Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients

NCT04079803 is registered in ClinicalTrials.gov with Cassava Sciences, Inc. as lead sponsor.

NCT NCT04079803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04079803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients
Lead sponsor
Cassava Sciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 9, 2019
Completion date
March 31, 2020
Enrollment
64 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease